RA disease impact in patients not treated with advanced therapies; survey findings from the National Rheumatoid Arthritis Society
by NRAS
Recently NICE published a Final Appraisal Document in respect of a new JAK inhibitor (filgotinib – Jyseleca) giving access to people with RA who have so called ‘moderate’ disease in addition to those with ‘severe’ disease. This is the first time NICE have broadened their eligibility criteria for access to advanced therapies and is warmly welcomed by NRAS. This comes at the same time as a paper published by the National Rheumatoid Arthritis Society (P.…
Read more of this article